Collagen Matrix Articles & Analysis
12 news found
Peptides are publicly accepted as promising cosmetic compounds with prominent roles in collagen production, anti-wrinkle activity, pigmentation reduction, firming, etc. ...
The novel implant’s architecture features a highly porous type I collagen matrix reinforced with bioresorbable PLLA microfilaments. The unique design of the BioBrace enables the mechanical reinforcement of soft tissue repairs, with a bio-inductive scaffold to promote healing. ...
GammaTile consists of 4 Cesium-131 sources embedded in a bioresorbable collagen matrix. Implanted at the time of brain tumor removal surgery, GammaTile immediately begins targeting any remaining tumor cells to inhibit tumor regrowth. ...
The novel biocomposite design of the BioBrace features a highly porous collagen matrix and resorbable PLLA microfilaments. This technical breakthrough results in a bio-inductive scaffold with strength, which is designed to both reinforce tendon and ligament repairs and promote healing. ...
The company has pioneered the BioBrace™ Implant, a breakthrough biocomposite scaffold featuring a highly-porous collagen matrix that is reinforced with bioresorbable microfilaments. The BioBrace Implant is intended to reinforce and regenerate soft tissue repairs in several clinical applications. ...
LymphBridge: Prospective Evaluation of the BioBridge Scaffold as an Adjunct to Lymph Node Transplant for Upper Extremity Lymphedema is an FDA approved clinical study that will assess Fibralign’s BioBridge Collagen Matrix for use in improving outcomes of surgical treatment of lymphedema. BioBridge is a sterile, biocompatible and biodegradable device made of ...
The company has pioneered the BioBrace™ Implant, a breakthrough biocomposite scaffold featuring a highly-porous collagen matrix that is reinforced with bioresorbable microfilaments. The BioBrace Implant is intended to reinforce and regenerate soft tissue repairs in several clinical applications. ...
Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first patient in a multi-site, randomized clinical trial in Europe evaluating its BioBridge® Collagen Matrix as a novel preventative treatment for secondary lymphedema. ...
Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first product, the BioBridge Collagen Matrix. BioBridge is classified as a Class III device with an indication for use to support lymphatic tissue repair and can be used after or in conjunction with surgical procedures ...
Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced today that it has executed a long term distributor agreement with Terumo Corporation to market and distribute the BioBridge® Collagen Matrix in Japan for treating and preventing secondary lymphedema. BioBridge is a sterile implantable biocompatible and ...
Fibralign has developed and established an end-to-end manufacturing system for production of its BioBridge Collagen Matrix in its GMP facility located in Union City, ...
The scope of the certification is for the design, development, manufacture and distribution of porcine collagen scaffold implants used for soft tissue repair and support, nerve repair, wound/scar management, orthopedics, vascular, ophthalmic and lymphatic therapeutic areas. Fibralign has developed and established an end-to-end manufacturing system for production of its BioBridge ...